Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Osteoporosis HELP
Based on 17,475 articles since 2008
||||

These are the 17475 published articles about Osteoporosis that originated from Worldwide during 2008-2017.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Osteoporosis management in patients with breast cancer: EMAS position statement. 2017

Trémollieres, Florence A / Ceausu, Iuliana / Depypere, Herman / Lambrinoudaki, Irene / Mueck, Alfred / Pérez-López, Faustino R / van der Schouw, Yvonne T / Senturk, Levent M / Simoncini, Tommaso / Stevenson, John C / Stute, Petra / Rees, Margaret. ·Menopause and Metabolic Bone Disease Unit, Hôpital Paule de Viguier, CHU Toulouse, Toulouse, France. Electronic address: tremollieres.fr@chu-toulouse.fr. · Department of Obstetrics and Gynecology, 'Carol Davila' University of Medicine and Pharmacy, and Department of Obstetrics and Gynecology, 'Dr. I. Cantacuzino' Hospital, Bucharest, Romania. · Breast Clinic and Menopause Clinic, University Hospital, De Pintelaan 185, 9000 Gent, Belgium. · Second Department of Obstetrics and Gynecology, National and Kapodestrian University of Athens, Greece. · University Women's Hospital of Tuebingen, Calwer Street 7, 72076 Tuebingen, Germany. · Department of Obstetrics and Gynecology, Zaragoza University Faculty of Medicine, Lozano-Blesa University Hospital, Zaragoza 50009, Spain. · Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. · Istanbul University Cerrahpasa School of Medicine. Dept. of Obstetrics and Gynecology, Division of Reproductive Endocrinology, IVF Unit, Istanbul, Turkey. · Department of Clinical and Experimental Medicine, University of Pisa, Via Roma, 67, 56100, Pisa, Italy. · National Heart and Lung Institute, Imperial College London, Royal Brompton Campus Hospital, London SW3 6NP, UK. · Department of Obstetrics and Gynecology, University Women's Hospital, Bern, Switzerland. · Women's Centre, John Radcliffe Hospital, Oxford OX3 9DU, UK. ·Maturitas · Pubmed #27802892.

ABSTRACT: Aromatase inhibitors (AIs) are the first-line recommended standard of care for postmenopausal estrogen receptor-positive breast cancer. Because they cause a profound suppression of estrogen levels, concerns regarding their potential to increase the risk of fracture were rapidly raised. There is currently a general consensus that a careful baseline evaluation is needed of the risk of fracture in postmenopausal women about to start treatment with AIs but also in all premenopausal women with early disease. Bisphosphonates have been shown in several phase III trials to prevent the bone loss induced by cancer treatment, although no fracture data are available. Even though they do not have regulatory approval for this indication, their use must be discussed with women at high risk of fracture. Accordingly, several guidelines recommend considering treatment in women with a T-score ≤-2 or those with two or more clinical risk factors. Moreover, recent data suggest that bisphosphonates, especially intravenous zoledronic acid, may have an anticancer effect, in that they reduce bone recurrence as well as extra-skeletal metastasis and breast cancer mortality in postmenopausal women. The anti-RANK ligand antibody denosumab is also emerging as a new adjuvant therapeutic option to prevent AI-induced bone loss. It has been shown to extend the time to first fracture in postmenopausal women treated with AIs. Several issues still need to be addressed regarding the use of these different agents in an adjuvant setting. The purpose of this position statement is to review the literature on antifracture therapy and to discuss the current guidelines for the management of osteoporosis in women with early breast cancer.

2 Guideline Best Practices for Dual-Energy X-ray Absorptiometry Measurement and Reporting: International Society for Clinical Densitometry Guidance. 2016

Lewiecki, E Michael / Binkley, Neil / Morgan, Sarah L / Shuhart, Christopher R / Camargos, Bruno Muzzi / Carey, John J / Gordon, Catherine M / Jankowski, Lawrence G / Lee, Joon-Kiong / Leslie, William D / Anonymous3330863. ·New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA. Electronic address: mlewiecki@gmail.com. · Osteoporosis Clinical Center and Research Program, University of Wisconsin, Madison, WI, USA. · Division of Clinical Immunology and Rheumatology, Department of Medicine, UAB Osteoporosis Prevention and Treatment Clinic, University of Alabama at Birmingham, Birmingham, AL, USA. · Swedish Medical Group, Seattle, WA, USA. · Rede Mater Dei de Saúde - Densimater, Belo Horizonte, Brazil. · Galway University Hospitals, National University of Ireland, Galway, Ireland. · Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA. · Illinois Bone and Joint Institute, LLC., Morton Grove, IL, USA. · JK Lee Orthopaedics & Traumatology, Petaling Jaya, Malaysia. · University of Manitoba, Winnipeg, Manitoba, Canada. · ·J Clin Densitom · Pubmed #27020004.

ABSTRACT: Dual-energy X-ray absorptiometry (DXA) is a technology that is widely used to diagnose osteoporosis, assess fracture risk, and monitor changes in bone mineral density (BMD). The clinical utility of DXA is highly dependent on the quality of the scan acquisition, analysis, and interpretation. Clinicians are best equipped to manage patients when BMD measurements are correct and interpretation follows well-established standards. Poor-quality acquisition, analysis, or interpretation of DXA data may mislead referring clinicians, resulting in unnecessary diagnostic evaluations, failure to evaluate when needed, inappropriate treatment, or failure to provide medical treatment, with potentially ineffective, harmful, or costly consequences. Misallocation of limited healthcare resources and poor treatment decisions can be minimized, and patient care optimized, through meticulous attention to DXA instrument calibration, data acquisition and analysis, interpretation, and reporting. This document from the International Society for Clinical Densitometry describes quality standards for BMD testing at DXA facilities worldwide to provide guidance for DXA supervisors, technologists, interpreters, and clinicians. High-quality DXA testing is necessary for correct diagnostic classification and optimal fracture risk assessment, and is essential for BMD monitoring.

3 Guideline American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. 2016

Runowicz, Carolyn D / Leach, Corinne R / Henry, N Lynn / Henry, Karen S / Mackey, Heather T / Cowens-Alvarado, Rebecca L / Cannady, Rachel S / Pratt-Chapman, Mandi L / Edge, Stephen B / Jacobs, Linda A / Hurria, Arti / Marks, Lawrence B / LaMonte, Samuel J / Warner, Ellen / Lyman, Gary H / Ganz, Patricia A. ·Carolyn D. Runowicz, Herbert Wertheim College of Medicine, Florida International University; Karen S. Henry, Sylvester Cancer Center at the University of Miami, Miami, FL; Corinne R. Leach, Rebecca L. Cowens-Alvarado, Rachel S. Cannady, and Samuel J. LaMonte, American Cancer Society, Atlanta, GA; N. Lynn Henry, University of Michigan, Comprehensive Cancer Center, Ann Arbor, MI; Heather T. Mackey, Oncology Nursing Society, Pittsburgh; Linda A. Jacobs, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Mandi L. Pratt-Chapman, The George Washington University Cancer Institute, Washington, DC; Stephen B. Edge, Baptist Cancer Center, Memphis, TN; Arti Hurria, City of Hope, Duarte; Patricia A. Ganz, Schools of Medicine and Public Health, University of California, Los Angeles, CA; Lawrence B. Marks, University of North Carolina, Chapel Hill, NC; Ellen Warner, University of Toronto, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; and Gary H. Lyman, Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, WA doi: 10.3322/caac.21319. Available online at cacancerjournal.com. · Carolyn D. Runowicz, Herbert Wertheim College of Medicine, Florida International University; Karen S. Henry, Sylvester Cancer Center at the University of Miami, Miami, FL; Corinne R. Leach, Rebecca L. Cowens-Alvarado, Rachel S. Cannady, and Samuel J. LaMonte, American Cancer Society, Atlanta, GA; N. Lynn Henry, University of Michigan, Comprehensive Cancer Center, Ann Arbor, MI; Heather T. Mackey, Oncology Nursing Society, Pittsburgh; Linda A. Jacobs, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Mandi L. Pratt-Chapman, The George Washington University Cancer Institute, Washington, DC; Stephen B. Edge, Baptist Cancer Center, Memphis, TN; Arti Hurria, City of Hope, Duarte; Patricia A. Ganz, Schools of Medicine and Public Health, University of California, Los Angeles, CA; Lawrence B. Marks, University of North Carolina, Chapel Hill, NC; Ellen Warner, University of Toronto, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; and Gary H. Lyman, Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, WA doi: 10.3322/caac.21319. Available online at cacancerjournal.com. corinne.leach@cancer.org. ·J Clin Oncol · Pubmed #26644543.

ABSTRACT: The purpose of the American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline is to provide recommendations to assist primary care and other clinicians in the care of female adult survivors of breast cancer. A systematic review of the literature was conducted using PubMed through April 2015. A multidisciplinary expert workgroup with expertise in primary care, gynecology, surgical oncology, medical oncology, radiation oncology, and nursing was formed and tasked with drafting the Breast Cancer Survivorship Care Guideline. A total of 1,073 articles met inclusion criteria; and, after full text review, 237 were included as the evidence base. Patients should undergo regular surveillance for breast cancer recurrence, including evaluation with a cancer-related history and physical examination, and should be screened for new primary breast cancer. Data do not support performing routine laboratory tests or imaging tests in asymptomatic patients to evaluate for breast cancer recurrence. Primary care clinicians should counsel patients about the importance of maintaining a healthy lifestyle, monitor for post-treatment symptoms that can adversely affect quality of life, and monitor for adherence to endocrine therapy. Recommendations provided in this guideline are based on current evidence in the literature and expert consensus opinion. Most of the evidence is not sufficient to warrant a strong evidence-based recommendation. Recommendations on surveillance for breast cancer recurrence, screening for second primary cancers, assessment and management of physical and psychosocial long-term and late effects of breast cancer and its treatment, health promotion, and care coordination/practice implications are made.This guideline was developed through a collaboration between the American Cancer Society and the American Society of Clinical Oncology and has been published jointly by invitation and consent in both CA: A Cancer Journal for Clinicians and Journal of Clinical Oncology. All rights reserved. No part of this document may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission by the American Cancer Society or the American Society of Clinical Oncology.

4 Guideline The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. 2016

Harbord, Marcus / Annese, Vito / Vavricka, Stephan R / Allez, Matthieu / Barreiro-de Acosta, Manuel / Boberg, Kirsten Muri / Burisch, Johan / De Vos, Martine / De Vries, Anne-Marie / Dick, Andrew D / Juillerat, Pascal / Karlsen, Tom H / Koutroubakis, Ioannis / Lakatos, Peter L / Orchard, Tim / Papay, Pavol / Raine, Tim / Reinshagen, Max / Thaci, Diamant / Tilg, Herbert / Carbonnel, Franck / Anonymous1101069. ·Department of Gastroenterology, Chelsea and Westminster NHS Foundation Trust, London, UK. · Department of Emergency, University Hospital Careggi, Florence, Italy. · Division of Gastroenterology and Hepatology, Triemli Hospital, Zurich, Switzerland. · Department of Gastroenterology, Hôpital Saint Louis, Sorbonne Paris-Cité University, Paris, France. · Department of Gastroenterology, University Hospital Santiago De Compostela, A Coruña, Spain. · Department of Transplantation Medicine, Division of Cancer Medicine, Surgery and Transplantation, Oslo University Hospital, Oslo, Norway Institute of Clinical Medicine, University of Oslo, Oslo, Norway. · Gastro Unit, Hvidovre University Hospital, Hvidovre, and Danish Centre for eHealth & Epidemiology, North Zealand University Hospital, Copenhagen, Denmark. · Department of Gastroenterology, University Hospital Ghent , Ghent, Belgium. · Department of Gastroenterology and Hepatology, University Medical Center Rotterdam, Rotterdam, The Netherlands. · Academic Unit of Ophthalmology, School of Clinical Sciences, Bristol, and National Institute for Health Research, Moorfield's Eye Hospital and UCL Institute of Ophthalmology, London, UK. · Clinic for Visceral Surgery and Medicine, University Hospital Bern, Bern, Switzerland. · Department of Gastroenterology, University Hospital Heraklion, Heraklion, Greece. · Department of Medicine I, Semmelweis University, Budapest, Hungary. · Imperial College Healthcare NHS Trust, St Mary's Hospital, London, UK. · Department of Internal Medicine, Hartmannspital Vienna, Vienna, Austria. · Department of Gastroenterology, Addenbrooke's Hospital, Cambridge, UK. · Medizinische Klinik I, Klinikum Braunschweig, Germany. · Comprehensive Center of Inflammation Medicine, University Hospital Schleswig Holstein, Lubeck, Germany. · Department of Internal Medicine, University Hospital Innsbruck, Innsbruck, Austria. · Service de Gastroentérologie CHU de Bicêtre, Université Paris Sud, Paris, France. · ·J Crohns Colitis · Pubmed #26614685.

ABSTRACT: -- No abstract --

5 Guideline Singapore Cancer Network (SCAN) Guidelines for Bisphosphonate Use in the Adjuvant Breast Cancer Setting. 2015

Anonymous661041. · ·Ann Acad Med Singapore · Pubmed #26763054.

ABSTRACT: INTRODUCTION: The SCAN breast cancer workgroup aimed to develop Singapore Cancer Network (SCAN) clinical practice guidelines regarding the optimal time-point for initiation of bisphosphonates when using adjuvant aromatase inhibitors (AIs) and provide a consensus for their role in modifying clinical breast cancer outcomes. MATERIALS AND METHODS: The workgroup utilised a modified ADAPTE process to calibrate high quality international evidence-based clinical practice guidelines to our local setting. RESULTS: Six international guidelines were evaluated-those developed by the National Cancer Comprehensive Network (2015), the European Society of Medical Oncology (2014), the National Institute for Clinical Evidence (2012), the Scottish Intercollegiate Guidelines Network (2013), the British Columbia Cancer Agency (2013) and the treatment algorithm based on the National Osteoporosis Foundation guidelines (2006). Recommendations on the use of bisphosphonates in postmenopausal women initiating adjuvant AIs in breast cancer to preserve bone health and the use of adjuvant bisphosphonates to improve breast cancer outcomes were developed. CONCLUSION: These adapted guidelines form the SCAN Guidelines on the use of adjuvant bisphosphonates to influence breast cancer outcomes and maintenance of bone health when on AIs.

6 Guideline Diagnosis and management of menopause: summary of NICE guidance. 2015

Sarri, Grammati / Davies, Melanie / Lumsden, Mary Ann / Anonymous1620849. ·National Collaborating Centre for Women's and Children's Health, Royal College of Gynaecologists and Obstetricians, London NW1 4RG, UK gsarri@rcog.org.uk. · National Collaborating Centre for Women's and Children's Health, Royal College of Gynaecologists and Obstetricians; University College London Hospitals, London, UK. · Reproductive and Maternal Medicine, University of Glasgow; Glasgow Royal Infirmary, Glasgow, UK. · ·BMJ · Pubmed #26563259.

ABSTRACT: -- No abstract --

7 Guideline Recommendations for preventing fracture in long-term care. 2015

Papaioannou, Alexandra / Santesso, Nancy / Morin, Suzanne N / Feldman, Sidney / Adachi, Jonathan D / Crilly, Richard / Giangregorio, Lora M / Jaglal, Susan / Josse, Robert G / Kaasalainen, Sharon / Katz, Paul / Moser, Andrea / Pickard, Laura / Weiler, Hope / Whiting, Susan / Skidmore, Carly J / Cheung, Angela M / Anonymous360843. ·Department of Medicine (Papaioannou, Adachi, Pickard), Department of Clinical Epidemiology and Biostatistics (Papaioannou, Santesso) and School of Nursing (Kaasalainen), Faculty of Health Sciences, McMaster University, Hamilton, Ont.; Geriatric Education and Research in Aging Sciences Centre (Papaioannou, Pickard, Skidmore), St. Peter's Hospital, Hamilton, Ont.; Department of Medicine (Morin), McGill University Health Centre, Montréal, Que.; Montreal General Hospital (Morin), Montréal, Que.; Department of Medicine (Feldman, Josse, Moser, Cheung) and Department of Physical Therapy (Jaglal), University of Toronto, Toronto, Ont.; Baycrest Geriatric Health Care System (Feldman, Katz, Moser), Toronto, Ont.; St. Joseph's Healthcare (Adachi), Hamilton, Ont.; Division of Geriatric Medicine, Department of Medicine (Crilly), University of Western Ontario, London, Ont.; Department of Kinesiology (Giangregorio), University of Waterloo, Waterloo, Ont.; Institute for Clinical Evaluative Sciences (Jaglal), Toronto, Ont.; Li Ka Shing Knowledge Institute (Josse), St Michael's Hospital, Toronto, Ont.; School of Dietetics and Human Nutrition (Weiler), McGill University, Montréal. Que.; Department of Nutrition and Dietetics (Whiting), University of Saskatchewan, Saskatoon, Sask.; Toronto General Hospital (Cheung), Toronto, Ont. papaioannou@hhsc.ca. · Department of Medicine (Papaioannou, Adachi, Pickard), Department of Clinical Epidemiology and Biostatistics (Papaioannou, Santesso) and School of Nursing (Kaasalainen), Faculty of Health Sciences, McMaster University, Hamilton, Ont.; Geriatric Education and Research in Aging Sciences Centre (Papaioannou, Pickard, Skidmore), St. Peter's Hospital, Hamilton, Ont.; Department of Medicine (Morin), McGill University Health Centre, Montréal, Que.; Montreal General Hospital (Morin), Montréal, Que.; Department of Medicine (Feldman, Josse, Moser, Cheung) and Department of Physical Therapy (Jaglal), University of Toronto, Toronto, Ont.; Baycrest Geriatric Health Care System (Feldman, Katz, Moser), Toronto, Ont.; St. Joseph's Healthcare (Adachi), Hamilton, Ont.; Division of Geriatric Medicine, Department of Medicine (Crilly), University of Western Ontario, London, Ont.; Department of Kinesiology (Giangregorio), University of Waterloo, Waterloo, Ont.; Institute for Clinical Evaluative Sciences (Jaglal), Toronto, Ont.; Li Ka Shing Knowledge Institute (Josse), St Michael's Hospital, Toronto, Ont.; School of Dietetics and Human Nutrition (Weiler), McGill University, Montréal. Que.; Department of Nutrition and Dietetics (Whiting), University of Saskatchewan, Saskatoon, Sask.; Toronto General Hospital (Cheung), Toronto, Ont. · ·CMAJ · Pubmed #26370055.

ABSTRACT: -- No abstract --

8 Guideline [SECOT-GEIOS guidelines in osteoporosis and fragility fracture. An update]. 2015

Etxebarria-Foronda, I / Caeiro-Rey, J R / Larrainzar-Garijo, R / Vaquero-Cervino, E / Roca-Ruiz, L / Mesa-Ramos, M / Merino Pérez, J / Carpintero-Benitez, P / Fernández Cebrián, A / Gil-Garay, E. ·Grupo de Estudio e Investigación de la Osteoporosis y la Fractura Osteoporótica de la Sociedad Española de Cirugía Ortopédica y Traumatología (GEIOS-SECOT), España; Servicio de Cirugía Ortopédica y Traumatología, Hospital Alto Deba, Arrasate-Mondragón, Gipuzkoa, España. Electronic address: ietxe@yahoo.es. · Grupo de Estudio e Investigación de la Osteoporosis y la Fractura Osteoporótica de la Sociedad Española de Cirugía Ortopédica y Traumatología (GEIOS-SECOT), España; Servicio de Cirugía Ortopédica y Traumatología, Complexo Hospitalario Universitario Santiago Compostela, Santiago de Compostela, A Coruña, España. · Grupo de Estudio e Investigación de la Osteoporosis y la Fractura Osteoporótica de la Sociedad Española de Cirugía Ortopédica y Traumatología (GEIOS-SECOT), España; Servicio de Cirugía Ortopédica y Traumatología, Hospital Universitario Infanta Leonor, Madrid, España. · Grupo de Estudio e Investigación de la Osteoporosis y la Fractura Osteoporótica de la Sociedad Española de Cirugía Ortopédica y Traumatología (GEIOS-SECOT), España; Servicio de Cirugía Ortopédica y Traumatología, Complexo Hospitalario Pontevedra, Pontevedra, España. · Grupo de Estudio e Investigación de la Osteoporosis y la Fractura Osteoporótica de la Sociedad Española de Cirugía Ortopédica y Traumatología (GEIOS-SECOT), España; Servicio de Cirugía Ortopédica y Traumatología, Hospital Universitario Virgen Macarena, Sevilla, España. · Grupo de Estudio e Investigación de la Osteoporosis y la Fractura Osteoporótica de la Sociedad Española de Cirugía Ortopédica y Traumatología (GEIOS-SECOT), España; Unidad de Gestión Clínica del Aparato Locomotor, Área Sanitaria Norte de Córdoba, Pozoblanco, Córdoba, España. · Grupo de Estudio e Investigación de la Osteoporosis y la Fractura Osteoporótica de la Sociedad Española de Cirugía Ortopédica y Traumatología (GEIOS-SECOT), España; Servicio de Cirugía Ortopédica y Traumatología, Hospital Universitario de Cruces, Barakaldo, Bizkaia, España. · Grupo de Estudio e Investigación de la Osteoporosis y la Fractura Osteoporótica de la Sociedad Española de Cirugía Ortopédica y Traumatología (GEIOS-SECOT), España; Cátedra de Cirugía Ortopédica y Traumatología, Facultad de Medicina, Córdoba, España. · Grupo de Estudio e Investigación de la Osteoporosis y la Fractura Osteoporótica de la Sociedad Española de Cirugía Ortopédica y Traumatología (GEIOS-SECOT), España; Servicio de Cirugía Ortopédica y Traumatología, Complejo Hospitalario de Ourense, Ourense, España. · Grupo de Estudio e Investigación de la Osteoporosis y la Fractura Osteoporótica de la Sociedad Española de Cirugía Ortopédica y Traumatología (GEIOS-SECOT), España; Servicio de Cirugía Ortopédica y Traumatología, Hospital Universitario La Paz, Madrid, España. ·Rev Esp Cir Ortop Traumatol · Pubmed #26233814.

ABSTRACT: -- No abstract --

9 Guideline 2015 Guidelines for Osteoporosis in Saudi Arabia: Recommendations from the Saudi Osteoporosis Society. 2015

Al-Saleh, Yousef / Sulimani, Riad / Sabico, Shaun / Raef, Hussein / Fouda, Mona / Alshahrani, Fahad / Al Shaker, Mohammad / Al Wahabi, Basma / Sadat-Ali, Mir / Al Rayes, Hanan / Al Aidarous, Salwa / Saleh, Siham / Al Ayoubi, Fakhr / Al-Daghri, Nasser M. ·Yousef Al-Saleh, MD, Assistant Professor,, College of Medicine,, King Saud bin Abdulaziz University for Health Sciences,, Riyadh, Saudi Arabia, T: +966(11)8011111 Ext.13056, F: +966(11)8011111 Ext. 14229, alaslawi@hotmail.com. · ·Ann Saudi Med · Pubmed #26142931.

ABSTRACT: BACKGROUND AND OBJECTIVES: To provide guidelines for medical professionals in Saudi Arabia regarding osteoporosis. DESIGN AND SETTINGS: A panel of 14 local experts in osteoporosis assembled to provide consensus based on the strength of evidence and expert opinions on osteoporosis treatment. PATIENTS AND METHODS: The Saudi Osteoporosis Society (SOS) formed a panel of experts who performed an extensive published studies search to formulate recommendations regarding prevention, diagnosis, and treatment of osteoporosis in Saudi Arabia. Both local and international published studies were utilized whenever available. RESULTS: Dual x-ray absorptiometry (DXA) scanning is still the golden standard for assessing bone mineral density (BMD). In the absence of local, country-specific fracture risk assessment tool (FRAX), the SOS recommends using the USA (White) version of the FRAX tool. All women above 60 years of age should be evaluated for BMD. This is because the panel recognized that osteoporosis and osteoporotic fractures occur at a younger age in Saudi Arabia. Hormone replacement therapy (HRT) is not recommended for treating postmenopausal women with osteoporosis. BMD evaluation should be performed 1-2 years after initiating intervention, and the assessment of bone turnover biomarkers should be performed whenever available to determine the efficacy of intervention. CONCLUSION: All Saudi women above the age of 60 years must undergo a BMD assessment using DXA. Therapy decisions should be formulated with the use of the USA (White) version of the FRAX tool.

10 Guideline [Update of recommendations for evaluation and treatment of osteoporosis associated to endocrine and nutritional conditions. Working Group on Osteoporosis and Mineral Metabolism of the Spanish Society of Endocrinology]. 2015

Reyes-García, Rebeca / García-Martín, Antonia / Varsavsky, Mariela / Rozas-Moreno, Pedro / Cortés-Berdonces, María / Luque-Fernández, Inés / Gómez Sáez, José Manuel / Vidal Casariego, Alfonso / Romero Muñoz, Manuel / Guadalix Iglesias, Sonsoles / Fernández García, Diego / Jódar Gimeno, Esteban / Muñoz Torres, Manuel / Anonymous310993. ·Unidad de Endocrinología, Hospital General Universitario Rafael Méndez, Lorca, Murcia, España; Unidad de Metabolismo Óseo, Servicio de Endocrinología, Hospital Universitario San Cecilio, Granada, España. Electronic address: rebecarg@yahoo.com. · Unidad de Metabolismo Óseo, Servicio de Endocrinología, Hospital Universitario San Cecilio, Granada, España; Unidad de Endocrinología, Hospital Comarcal del Noroeste, Caravaca de la Cruz, Murcia, España. · Servicio de Endocrinología, Hospital de Sant Pau i Santa Tecla, Tarragona, España. · Unidad de Metabolismo Óseo, Servicio de Endocrinología, Hospital Universitario San Cecilio, Granada, España; Servicio de Endocrinología, Hospital General de Ciudad Real, Ciudad Real, España. · Unidad de Endocrinología, Centro de Endocrinología, Diabetes y Nutrición, Madrid, España. · Servicio de Endocrinología, Hospital Virgen de la Salud de Toledo, Toledo, España. · Servicio de Endocrinología, Hospital Universitario de Bellvitge, Barcelona, España. · Sección de Endocrinología, Complejo Asistencial Universitario de León, León, España. · Unidad de Endocrinología, Hospital General Universitario Rafael Méndez, Lorca, Murcia, España. · Servicio de Endocrinología, Hospital Doce de Octubre, Madrid, España. · Servicio de Endocrinología, Hospital Universitario Virgen de la Victoria, Málaga, España. · Servicio de Endocrinología, Hospital Universitario Quiron, Madrid, España. · Unidad de Metabolismo Óseo, Servicio de Endocrinología, Hospital Universitario San Cecilio, Granada, España. · ·Endocrinol Nutr · Pubmed #25797189.

ABSTRACT: OBJECTIVE: To update previous recommendations developed by the Working Group on Osteoporosis and Mineral Metabolism of the Spanish Society of Endocrinology and Nutrition for the evaluation and treatment of osteoporosis associated to different endocrine and nutritional diseases. PARTICIPANTS: Members of the Working Group on Osteoporosis and Mineral Metabolism of the Spanish Society of Endocrinology and Nutrition. METHODS: Recommendations were formulated according to the GRADE system (Grading of Recommendations, Assessment, Development, and Evaluation) to describe both the strength of recommendations and the quality of evidence. A systematic search was made in MEDLINE (Pubmed) using the following terms associated to the name of each condition: AND "osteoporosis", "fractures", "bone mineral density", and "treatment". Papers in English with publication date between 18 October 2011 and 30 October 2014 were included. The recommendations were discussed and approved by all members of the Working Group. CONCLUSIONS: This update summarizes the new data regarding evaluation and treatment of osteoporosis associated to endocrine and nutritional conditions.

11 Guideline [Clinical practice guideline. Diagnosis and treatment of postmenopausal and perinemopausia]. 2015

Alvarado-García, Alberto / Hernández-Quijano, Tomás / Hernández-Valencia, Marcelino / Negrín-Pérez, Miriam Concepción / Ríos-Castillo, Brendha / Valencia-Pérez, Gregorio Urbano / Vital-Reyes, Víctor Saúl / Basavilvazo-Rodríguez, María Antonia / Torres-Arreola, Laura Pilar / Ortiz-Luna, Guillermo Federico / Sánchez-Aguirre, Fernando / Montaño-Uscanga, Armando. ·Asociación Mexicana para el Estudio del Climaterio, Distrito Federal, México. dra.basa06@gmail.com. · ·Rev Med Inst Mex Seguro Soc · Pubmed #25760751.

ABSTRACT: Post-menopause is the period of life where a deep decline occurs in circulating estrogen levels, inducing the appearance of psycho and somatic symptoms. The classification to understand the chronology of reproductive aging in women (known as STRAW) determines the clinical and endocrine changes contemplating menstrual cycles, symptoms, measurements of FSH, LH, inhibin B, anti-Mullerian hormone , and follicular account. The diagnosis of menopause is established by the absence of menstruation for 12 months or more. The most frequent clinical manifestations of the climacteric syndrome transition to menopause are menstrual disorders, vasomotor symptoms (flushes and/or sweats) and genitourinary manifestations. The assessment of women in the peri- or postmenopause aims to develop: cervicovaginal cytology , lipid profile , serum glucose, basal Mammography at least a year before, pelvic ultrasound, urinalysis, serum TSH, Densitometry in patients older than 60 years if there is no recourse can be applied and FRAX. Drug therapy for the treatment of disorders of the transition to menopause or menopause is divided into: hormone therapy (HT) based estrogens and progestin hormone not being the most recommended the serotonin reuptake inhibitors and norepinephrine, clonidine, gabapentin or veralipride.

12 Guideline EMAS position statement: The ten point guide to the integral management of menopausal health. 2015

Neves-E-Castro, Manuel / Birkhauser, Martin / Samsioe, Goran / Lambrinoudaki, Irene / Palacios, Santiago / Borrego, Rafael Sanchez / Llaneza, Placido / Ceausu, Iuliana / Depypere, Herman / Erel, C Tamer / Pérez-López, Faustino R / Schenck-Gustafsson, Karin / van der Schouw, Yvonne T / Simoncini, Tommaso / Tremollieres, Florence / Rees, Margaret. ·Clinica da Menopausa, Av. Luis Bivar, 93c-1 Dt, Lisboa 1050-143, Portugal. · Gynaecological Endocrinology and Reproductive Medicine, University of Berne, Gartenstrasse 67, CH-4052 Basel, Switzerland. · Department of Clinical Sciences, SUS University Hospital Lund, Lund University, SE-221 85 Lund, Sweden. · Second Department of Obstetrics and Gynecology, National and Capodestrian University of Athens, Greece. · Instituto Palacios, Salud y Medicina de la Mujer, C/Antonio Acuña, 9, 28009 Madrid, Spain. · DIATROS, Clínica de Atención a la Mujer, Barcelona, Spain. · Department of Obstetrics and Gynecology, University Central Hospital of Asturias, University of Oviedo, 33011 Oviedo, Spain. · Department of Obstetrics and Gynecology, 'Carol Davila' University of Medicine and Pharmacy, Bucharest, Romania; Department of Obstetrics and Gynecology, 'Dr. I. Cantacuzino' Hospital, Bucharest, Romania. · Breast Clinic and Menopause Clinic, University Hospital, De Pintelaan 185, 9000 Gent, Belgium. · Department of Obstetrics and Gynecology, Istanbul University, Cerrahpasa School of Medicine, Valikonagi Cad. No: 93/4, Nisantasi, 34365 Istanbul, Turkey. · Department of Obstetrics and Gynecology, Zaragoza University Facultad de Medicina, Hospital Clínico, Zaragoza 50009, Spain. · Department of Medicine, Cardiology Unit, Centre for Gender Medicine, Karolinska Institutet and Karolinska University Hospital, Thorax N3:05, SE 17176 Stockholm, Sweden. · Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. · Department of Clinical and Experimental Medicine, University of Pisa, Via Roma, 67, 56100 Pisa, Italy. · Menopause and Metabolic Bone Disease Unit, Hôpital Paule de Viguier, F-31059 Toulouse cedex 09, France. · Women's Centre, John Radcliffe Hospital, Oxford OX3 9DU, UK. Electronic address: margaret.rees@st-hildas.ox.ac.uk. ·Maturitas · Pubmed #25757366.

ABSTRACT: With increased longevity and more women becoming centenarians, management of the menopause and postreproductive health is of growing importance as it has the potential to help promote health over several decades. Women have individual needs and the approach needs to be personalised. The position statement provides a short integral guide for all those involved in menopausal health. It covers diagnosis, screening for diseases in later life, treatment and follow-up.

13 Guideline 2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis. 2014

Briot, Karine / Cortet, Bernard / Roux, Christian / Fardet, Laurence / Abitbol, Vered / Bacchetta, Justine / Buchon, Daniel / Debiais, Francoise / Guggenbuhl, Pascal / Laroche, Michel / Legrand, Erik / Lespessailles, Eric / Marcelli, Christian / Weryha, Georges / Thomas, Thierry / Anonymous340814. · ·Joint Bone Spine · Pubmed #25455041.

ABSTRACT: OBJECTIVES: To update the recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis issued in 2003 by the French National Authority for Health (HAS). This update was performed under the aegis of the Bone Section of the French Society for Rheumatology (SFR) and Osteoporosis Research and Information Group (GRIO), in collaboration with four French learned societies (primary-care, gastroenterology, internal medicine, and nephrology). METHODS: A task force composed of members of the medical specialties involved in managing patients with glucocorticoid-induced osteoporosis conducted a systematic literature review according to the method developed by the HAS then used the results to develop updated recommendations. RESULTS: These recommendations are intended for all physicians involved in the management of patients who are scheduled to start, or are taking, long-term glucocorticoid therapy (≥ 3 months) in any dose and for any reason. In postmenopausal women and men older than 50 years of age, treatment is warranted in the presence of any of the following risk factors for fracture: history of bone frailty fracture after 50 years of age, bone mineral density T-score ≤ −2.5 at one or more sites, age ≥ 70 years, and dosage ≥ 7.5 mg/d prednisone-equivalent for longer than 3 months. Bisphosphonates can be used in all these situations; teriparatide can be given as first-line therapy in patients at high fracture risk but is reimbursed by the French statutory health insurance system only in patients having two or more prevalent vertebral fractures. The fracture risk is lower in non-menopausal women and in men younger than 50 years of age,in whom treatment decisions should rest on a case-by-case evaluation. CONCLUSION: These recommendations are intended to clarify the pharmacological management of glucocorticoid-induced osteoporosis.

14 Guideline American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. 2014

Ruggiero, Salvatore L / Dodson, Thomas B / Fantasia, John / Goodday, Reginald / Aghaloo, Tara / Mehrotra, Bhoomi / O'Ryan, Felice / Anonymous1480807. ·Clinical Professor, Division of Oral and Maxillofacial Surgery, Stony Brook School of Dental Medicine, Hofstra North Shore-LIJ School of Medicine, New York Center for Orthognathic and Maxillofacial Surgery, Lake Success, NY. Electronic address: sruggie@optonline.net. · Professor and Chair, Associate Dean for Hospital Affairs, Department of Oral and Maxillofacial Surgery, University of Washington School of Dentistry, Seattle, WA. · Chief, Division of Oral Pathology, Department of Dental Medicine, Hofstra North Shore-LIJ School of Medicine , New Hyde Park, NY. · Professor, Department of Oral and Maxillofacial Sciences, Dalhousie University, Halifax, NS, Canada. · Associate Professor, Oral and Maxillofacial Surgery, Assistant Dean for Clinical Research, UCLA School of Dentistry, Los Angeles, CA. · Director, Cancer Institute at St Francis Hospital, Roslyn, NY. · Director, Division of Maxillofacial Surgery, Kaiser Permanente Oakland Medical Center, Oakland, CA. · ·J Oral Maxillofac Surg · Pubmed #25234529.

ABSTRACT: Strategies for management of patients with, or at risk for, medication-related osteonecrosis of the jaw (MRONJ) were set forth in the American Association of Oral and Maxillofacial Surgeons (AAOMS) position papers in 2007 and 2009. The position papers were developed by a special committee appointed by the board and composed of clinicians with extensive experience in caring for these patients and basic science researchers. The knowledge base and experience in addressing MRONJ has expanded, necessitating modifications and refinements to the previous position paper. This special committee met in September 2013 to appraise the current literature and revise the guidelines as indicated to reflect current knowledge in this field. This update contains revisions to diagnosis, staging, and management strategies and highlights current research status. The AAOMS considers it vitally important that this information be disseminated to other relevant health care professionals and organizations.

15 Guideline Osteoporosis in menopause. 2014

Khan, Aliya / Fortier, Michel / Anonymous761111. ·Hamilton ON. · Quebec QC. · ·J Obstet Gynaecol Can · Pubmed #25222365.

ABSTRACT: OBJECTIVE: To provide guidelines for the health care provider on the prevention, diagnosis, and clinical management of postmenopausal osteoporosis. OUTCOMES: Strategies for identifying and evaluating high-risk individuals, the use of bone mineral density (BMD) and bone turnover markers in assessing diagnosis and response to management, and recommendations regarding nutrition, physical activity, and the selection of pharmacologic therapy to prevent and manage osteoporosis. EVIDENCE: Published literature was retrieved through searches of PubMed and The Cochrane Library on August 30 and September 18, 2012, respectively. The strategy included the use of appropriate controlled vocabulary (e.g., oteoporosis, bone density, menopause) and key words (e.g., bone health, bone loss, BMD). Results were restricted to systematic reviews, practice guidelines, randomized and controlled clinical trials, and observational studies published in English or French. The search was limited to the publication years 2009 and following, and updates were incorporated into the guideline to March 2013. Grey (unpublished) literature was identified through searching the websites of health technology assessment and health technology assessment-related agencies, clinical practice guideline collections, clinical trial registries, and national and international medical specialty societies.

16 Guideline [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 3 Clinical symptoms]. 2014

Kiltz, U / Rudwaleit, M / Sieper, J / Krause, D / Chenot, J-F / Stallmach, A / Jaresch, S / Oberschelp, U / Schneider, E / Swoboda, B / Böhm, H / Heiligenhaus, A / Pleyer, U / Böhncke, W-H / Stemmer, M / Braun, J / Anonymous4290805. ·Deutsche Gesellschaft für Rheumatologie (DGRh), -, -, Uta.Kiltz@elisabethgruppe.de. · ·Z Rheumatol · Pubmed #25181971.

ABSTRACT: -- No abstract --

17 Guideline Recommendations of the Brazilian Society of Endocrinology and Metabology (SBEM) for the diagnosis and treatment of hypovitaminosis D. 2014

Maeda, Sergio Setsuo / Borba, Victoria Z C / Camargo, Marília Brasilio Rodrigues / Silva, Dalisbor Marcelo Weber / Borges, João Lindolfo Cunha / Bandeira, Francisco / Lazaretti-Castro, Marise / Anonymous10805. ·Disciplina de Endocrinologia, Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo, SP, Brasil. · Departamento de Clínica Médica, Universidade Federal do Paraná, Curitiba, PR, Brasil. · Departamento de Clínica Médica, Faculdade de Medicina da Univille, Joinville, SC, Brasil. · Disciplina de Endocrinologia, Universidade Católica de Brasília, Brasília, DF, Brasil. · Disciplina de Endocrinologia, Hospital Agamenon Magalhães, Escola de Medicina, Universidade de Pernambuco, Recife, PE, Brasil. · ·Arq Bras Endocrinol Metabol · Pubmed #25166032.

ABSTRACT: OBJECTIVE: The objective is to present an update on the diagnosis and treatment of hypovitaminosis D, based on the most recent scientific evidence. MATERIALS AND METHODS: The Department of Bone and Mineral Metabolism of the Brazilian Society of Endocrinology and Metabology (SBEM) was invited to generate a document following the rules of the Brazilian Medical Association (AMB) Guidelines Program. Data search was performed using PubMed, Lilacs and SciELO and the evidence was classified in recommendation levels, according to the scientific strength and study type. CONCLUSION: A scientific update regarding hypovitaminosis D was presented to serve as the basis for the diagnosis and treatment of this condition in Brazil.

18 Guideline National Osteoporosis Society vitamin D guideline summary. 2014

Aspray, Terry J / Bowring, Claire / Fraser, William / Gittoes, Neil / Javaid, M Kassim / Macdonald, Helen / Patel, Sanjeev / Selby, Peter / Tanna, Nuttan / Francis, Roger M / Anonymous1210802. ·The Bone Clinic, Musculoskeletal Unit, Freeman Hospital, Newcastle upon Tyne, UK Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, UK. · National Osteoporosis Society, Bath BA2 0PJ, UK. · Norwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK. · Department of Medicine, University Hospitals Birmingham, Birmingham B15 2TH, UK. · NIHR BRU, NDORMS, University of Oxford, Nuffield Orthopaedic Centre, OXFORD, OX3 7HE, UK. · Musculoskeletal Research, University of Aberdeen, Aberdeen AB25 2ZD, UK. · Department of Rheumatology, Epsom & St Helier University Hospital, Carshalton, Surrey SM5 3AA, UK. · Department of Medicine, Manchester Royal Infirmary, Oxford Road, Manchester, UK. · Women's Services & Arthritis Centre, N W London Hospitals NHS Trust, Harrow, Middlesex, UK. · Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, UK. · ·Age Ageing · Pubmed #25074538.

ABSTRACT: The National Osteoporosis Society (NOS) published its document, Vitamin D and Bone Health: A Practical Clinical Guideline for Patient Management, in 2013 as a practical clinical guideline on the management of vitamin D deficiency in adult patients with, or at risk of developing, bone disease. There has been no clear consensus in the UK on vitamin D deficiency its assessment and treatment, and clinical practice is inconsistent. This guideline is aimed at clinicians, including doctors, nurses and dieticians. It recommends the measurement of serum 25 (OH) vitamin D (25OHD) to estimate vitamin D status in the following clinical scenarios: bone diseases that may be improved with vitamin D treatment; bone diseases, prior to specific treatment where correcting vitamin D deficiency is appropriate; musculoskeletal symptoms that could be attributed to vitamin D deficiency. The guideline also states that routine vitamin D testing is unnecessary where vitamin D supplementation with an oral antiresorptive treatment is already planned and sets the following serum 25OHD thresholds: <30 nmol/l is deficient; 30-50 nmol/l may be inadequate in some people; >50 nmol/l is sufficient for almost the whole population. For treatment, oral vitamin D3 is recommended with fixed loading doses of oral vitamin D3 followed by regular maintenance therapy when rapid correction of vitamin D deficiency is required, although loading doses are not necessary where correction of deficiency is less urgent or when co-prescribing with an oral antiresorptive agent. For monitoring, serum calcium (adjusted for albumin) should be checked 1 month after completing a loading regimen, or after starting vitamin D supplementation, in case primary hyperparathyroidism has been unmasked. However, routine monitoring of serum 25OHD is generally unnecessary but may be appropriate in patients with symptomatic vitamin D deficiency or malabsorption and where poor compliance with medication is suspected. The guideline focuses on bone health as, although there are numerous putative effects of vitamin D on immunity modulation, cancer prevention and the risks of cardiovascular disease and multiple sclerosis, there remains considerable debate about the evaluation of extraskeletal factors and optimal vitamin D status in these circumstances.

19 Guideline Spanish Menopause Society position statement: Use of denosumab in postmenopausal women. 2014

Cano, Antonio / Silvan, José Manuel / Estévez, Antonio / Baró, Francesc / Villero, José / Quereda, Francisco / Ferrer, Javier / Mendoza, Nicolás / Sánchez-Borrego, Rafael / Anonymous1130801. ·Hospital Universitario Dr Peset, University of Valencia, Valencia, Spain. Electronic address: Antonio.Cano@uv.es. · Hospital Universitario Virgen del Rocío, University of Seville, Seville, Spain. Electronic address: jsilvana@sego.es. · Hospital Universitario de Valme, Seville, Spain. Electronic address: antonioestevezgon@gmail.com. · Hospital Vall d́Hebron, University of Barcelone, Barcelone, Spain. Electronic address: fbaromar@gmail.com. · Hospital Reina Sofía, Córdoba, Spain. Electronic address: jville@teleline.es. · Hospital Universitario San Juan, Alicante, University Miguel Hernández, Alicante, Spain. Electronic address: fqueredas@sego.es. · Hospital Universitario Central de Asturias, University of Oviedo, Spain. Electronic address: fjferrer@uniovi.es. · Clinica Margen, Department of Obstetrics and Gynecology, University of Granada, Granada, Spain. Electronic address: nicomendoza@telefonica.net. · Clínica Diatros, Barcelone, Spain. Electronic address: rschez.borrego@diatros.com. · ·Maturitas · Pubmed #25042873.

ABSTRACT: Denosumab is a new drug developed for the treatment of osteoporosis. Moreover, increasing evidences link denosumab with benefits in cancer, an area of interest for those in charge of the postmenopausal health. Denosumab has shown efficacy in the control of bone loss associated with hypogonadic states created by chemotherapy in breast and other cancers. Moreover, some studies reveal efficacy in reducing the progression of metastases. A panel of experts from the Spanish Menopause Society has met to develop usage recommendations based on the best available evidence.

20 Guideline [Preventive activities in women]. 2014

López García-Franco, Alberto / Arribas Mir, Lorenzo / del Cura González, Isabel / Bailón Muñoz, Emilia / Iglesias Piñeiro, M José / Gutiérrez Teira, Blanca / Landa Goñi, Jacinta / Ojuel Solsona, Julia / Fuentes Pujol, Mercè / Alonso Coello, Pablo / Anonymous2670798. ·Grupo de la Mujer del PAPPS. · ·Aten Primaria · Pubmed #24950633.

ABSTRACT: -- No abstract --

21 Guideline Bone health in cancer patients: ESMO Clinical Practice Guidelines. 2014

Coleman, R / Body, J J / Aapro, M / Hadji, P / Herrstedt, J / Anonymous490793. ·Weston Park Hospital, Cancer Research-UK/Yorkshire Cancer Research Sheffield Cancer Research Centre, Sheffield, UK. · CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium. · Multidisciplinary Oncology Institute, Genolier, Switzerland. · Department of Gynecology, Endocrinology and Oncology, Philipps-University of Marburg, Marburg, Germany. · Department of Oncology, Odense University Hospital, Odense, Denmark. · ·Ann Oncol · Pubmed #24782453.

ABSTRACT: There are three distinct areas of cancer management that make bone health in cancer patients of increasing clinical importance. First, bone metastases are common in many solid tumours, notably those arising from the breast, prostate and lung, as well as multiple myeloma, and may cause major morbidity including fractures, severe pain, nerve compression and hypercalcaemia. Through optimum multidisciplinary management of patients with bone metastases, including the use of bone-targeted treatments such as potent bisphosphonates or denosumab, it has been possible to transform the course of advanced cancer for many patients resulting in a major reduction in skeletal complications, reduced bone pain and improved quality of life. Secondly, many of the treatments we use to treat cancer patients have effects on reproductive hormones, which are critical for the maintenance of normal bone remodelling. This endocrine disturbance results in accelerated bone loss and an increased risk of osteoporosis and fractures that can have a significant negative impact on the lives of the rapidly expanding number of long-term cancer survivors. Finally, the bone marrow micro-environment is also intimately involved in the metastatic processes required for cancer dissemination, and there are emerging data showing that, at least in some clinical situations, the use of bone-targeted treatments can reduce metastasis to bone and has potential impact on patient survival.

22 Guideline Polish guidelines for the diagnosis and management of osteoporosis: a review of 2013 update. 2014

Głuszko, Piotr / Lorenc, Roman S / Karczmarewicz, Elżbieta / Misiorowski, Waldemar / Jaworski, Maciej / Anonymous591074. · ·Pol Arch Med Wewn · Pubmed #24694725.

ABSTRACT: To decrease the risk of osteoporotic fractures in Poland, the Multidisciplinary Osteoporotic Forum has set up a joint Working Group including the representatives of the Polish Associations of Orthopedics and Traumatology, Rehabilitation, Gerontology, Rheumatology, Family Medicine, Diabetology, Laboratory Diagnostics, Andropause and Menopause, Endocrinology, Radiology, and the STENKO group as well as experts in the fields of rheumatology, obstetrics, and geriatrics to update the Polish guidelines for the diagnosis and management of osteoporosis in men and postmenopausal women in Poland. The assessment of fracture risk and intervention thresholds was made using the FRAX® calculation tool for Poland. The strength of recommendations was evaluated according to the principles of the Scottish Intercollegiate Guidelines Network and the results have been approved by national consultants. Finally, the Working Group has formulated the updated guidelines and recommended two -step diagnostic and therapeutic procedures. The first stage applies to family physicians or general practitioners and involves the assessment of fracture risk using the FRAX®-BMI to identify patients at high risk of fractures. An osteoporotic fracture remains an absolute indication both for the general practitioner and specialist to implement treatment. At the second stage, the specialist (in an osteoporosis or other specialty clinic) should review the primary or secondary causes of fracture risk, confirm the diagnosis, and introduce an appropriate treatment and monitoring. In patients (men aged >50 years and postmenopausal women) without low-energy fractures, the absolute risk of fractures exceeding 10% should be considered an indication for treatment. The Polish guidelines were compared with other international guidelines in terms of diagnostic measures, pharmacotherapy, as well as calcium and vitamin D supplementation.

23 Guideline EMAS position statement: The management of postmenopausal women with vertebral osteoporotic fracture. 2014

Triantafyllopoulos, Ioannis K / Lambropoulou-Adamidou, Kalliopi / Nacopoulos, Cleopatra C / Papaioannou, Nikolaos A / Ceausu, Iuliana / Depypere, Herman / Erel, C Tamer / Pérez-López, Faustino R / Schenck-Gustafsson, Karin / van der Schouw, Yvonne T / Simoncini, Tommaso / Tremollieres, Florence / Rees, Margaret / Lambrinoudaki, Irene / Anonymous6960789. ·Laboratory of Research for the Musculoskeletal System (LRMS), School of Medicine, University of Athens, 10 Athinas Street, 14561 Kifissia, Greece. Electronic address: sportdoc@otenet.gr. · Medical School, University of Athens, KAT General Hospital, 2 Nikis Street, 14561 Kifissia, Greece. · Medical School, University of Athens, 10 Athinas Street, 14561 Kifissia, Greece. · Laboratory of Research for the Musculoskeletal System (LRMS), School of Medicine, University of Athens, 10 Athinas Street, 14561 Kifissia, Greece. · Department of Obstetrics and Gynecology, 'Carol Davila' University of Medicine and Pharmacy, Bucharest, Romania; Department of Obstetrics and Gynecology, 'Dr. I. Cantacuzino' Hospital, Bucharest, Romania. · Breast Clinic and Menopause Clinic, University Hospital, De Pintelaan 185, 9000 Gent, Belgium. · Department of Obstetrics and Gynecology, Istanbul University, Cerrahpasa School of Medicine, Valikonagi Cad. No. 93/4, Nisantasi, 34365 Istanbul, Turkey. · Department of Obstetrics and Gynecology, Zaragoza University Facultad de Medicina, Hospital Clínico, Zaragoza 50009, Spain. · Department of Medicine, Cardiology Unit and Head Centre for Gender Medicine, Karolinska Institutet and Karolinska University Hospital, Thorax N3:06, SE 17176 Stockholm, Sweden. · Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. · Department of Clinical and Experimental Medicine, University of Pisa, Via Roma, 67, 56100 Pisa, Italy. · Menopause and Metabolic Bone Disease Unit, Hôpital Paule de Viguier, F-31059 Toulouse cedex 09, France. · Women's Centre, John Radcliffe Hospital, Oxford OX3 9DU, UK. · Second Department of Obstetrics and Gynecology, National and Capodestrian University of Athens, Greece. · ·Maturitas · Pubmed #24679890.

ABSTRACT: INTRODUCTION: Osteoporotic vertebral fractures are associated with significant morbidity, excess mortality as well as health and social service expenditure. Additionally, women with a prevalent osteoporotic vertebral fracture have a high risk of experiencing a further one within one year. It is therefore important for the physician to use a diagnostic and therapeutic algorithm for early detection and effective treatment of vertebral fractures. AIMS: The aim of this position statement is to provide and critically appraise evidence on the management of women with a vertebral osteoporotic fracture. MATERIALS AND METHODS: Literature review and consensus of expert opinion. RESULTS AND CONCLUSIONS: The management of women with osteoporotic vertebral fractures includes measures to reduce pain providing early mobility, to support the affected spine ensuring fracture healing, as well as starting treatment for osteoporosis itself. Any other underlying pathology should be sought and treated. Early detection and treatment is essential as there is an increased risk of further fractures in patients with vertebral fractures. Treatment will depend on the underlying causes of bone loss, efficacy in any particular situation, cost and patient preference.

24 Guideline EMAS position statement: Menopause for medical students. 2014

Brockie, Janet / Lambrinoudaki, Irene / Ceausu, Iuliana / Depypere, Herman / Erel, C Tamer / Pérez-López, Faustino R / Schenck-Gustafsson, Karin / van der Schouw, Yvonne T / Simoncini, Tommaso / Tremollieres, Florence / Rees, Margaret / Anonymous2740788. ·Women's Centre, John Radcliffe Hospital, Oxford OX3 9DU, UK. Electronic address: janet.brockie@ouh.nhs.uk. · Second Department of Obstetrics and Gynecology, National and Capodestrian University of Athens, Greece. · Department of Obstetrics and Gynecology, 'Carol Davila' University of Medicine and Pharmacy, Romania; Department of Obstetrics and Gynecology, 'Dr. I. Cantacuzino' Hospital, Bucharest, Romania. · Breast Clinic and Menopause Clinic, University Hospital, De Pintelaan 185, 9000 Gent, Belgium. · Department of Obstetrics and Gynecology, Istanbul University, Cerrahpasa School of Medicine, Valikonagi Cad. No. 93/4, Nisantasi, 34365 Istanbul, Turkey. · Department of Obstetrics and Gynecology, Zaragoza University Facultad de Medicina, Hospital Clínico, Zaragoza 50009, Spain. · Department of Medicine, Cardiology Unit and Head Centre for Gender Medicine, Karolinska Institutet and Karolinska University Hospital, Thorax N3:06, SE 17176 Stockholm, Sweden. · Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands. · Department of Clinical and Experimental Medicine, University of Pisa, Via Roma, 67, 56100 Pisa, Italy. · Menopause and Metabolic Bone Disease Unit, Hôpital Paule de Viguier, F-31059 Toulouse cedex 09, France. · Women's Centre, John Radcliffe Hospital, Oxford OX3 9DU, UK. · ·Maturitas · Pubmed #24630127.

ABSTRACT: -- No abstract --

25 Guideline 2014 Female Athlete Triad Coalition consensus statement on treatment and return to play of the female athlete triad: 1st International Conference held in San Francisco, CA, May 2012, and 2nd International Conference held in Indianapolis, IN, May 2013. 2014

De Souza, Mary Jane / Nattiv, Aurelia / Joy, Elizabeth / Misra, Madhusmita / Williams, Nancy I / Mallinson, Rebecca J / Gibbs, Jenna C / Olmsted, Marion / Goolsby, Marci / Matheson, Gordon / Anonymous3170786 / Anonymous3180786 / Anonymous3190786 / Anonymous3200786. ·*Penn State University, Department of Kinesiology, University Park, Pennsylvania; †University of California Los Angeles, Los Angeles, California; ‡Intermountain Healthcare, Salt Lake City, Utah; §Harvard Medical School, Boston, Massachusetts; ¶University of Waterloo, Waterloo, Ontario, Canada; ‖University of Toronto, Toronto, Ontario, Canada; **Hospital for Special Surgery, New York, New York; ††Stanford University, Stanford, California. · ·Clin J Sport Med · Pubmed #24569429.

ABSTRACT: The Female Athlete Triad is a medical condition often observed in physically active girls and women, and involves 3 components: (1) low energy availability with or without disordered eating, (2) menstrual dysfunction, and (3) low bone mineral density. Female athletes often present with 1 or more of the 3 Triad components, and an early intervention is essential to prevent its progression to serious endpoints that include clinical eating disorders, amenorrhea, and osteoporosis. This consensus statement represents a set of recommendations developed following the first (San Francisco, California) and second (Indianapolis, Indianna) International Symposia on the Female Athlete Triad. It is intended to provide clinical guidelines for physicians, athletic trainers, and other health care providers for the screening, diagnosis, and treatment of the Female Athlete Triad and to provide clear recommendations for return to play. The 2014 Female Athlete Triad Coalition Consensus Statement on Treatment and Return to Play of the Female Athlete Triad Expert Panel has proposed a risk stratification point system that takes into account magnitude of risk to assist the physician in decision-making regarding sport participation, clearance, and return to play. Guidelines are offered for clearance categories, management by a multidisciplinary team, and implementation of treatment contracts. This consensus paper has been endorsed by The Female Athlete Triad Coalition, an International Consortium of leading Triad researchers, physicians, and other health care professionals, the American College of Sports Medicine, and the American Medical Society for Sports Medicine.

Next